ArticlePituitary2025
Good response rates and predictors during the first year of cabergoline treatment in large invasive prolactinomas.
Article in Pituitary, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Gonadal recovery in men with prolactinomas on cabergoline: 6-month testosterone levels as a predictor of testosterone replacement timing.Hormones (Athens, Greece) · 2026Article
- Prolactin secreting pituitary neuroendocrine tumors treated by dopamine agonists: predictors of response.Frontiers in endocrinology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe factors predicting the long-term response to cabergoline are not well known, particularly in more invasive prolactinomas. This study aimed to evaluate the rate of good response (GR) (normoprolactinemia and ≥ 50% tumor shrinkage) at the one-year follow-up and to identify predictors of GR in patients with large invasive prolactinomas.
methodsThis retrospective single-center study included 38 patients (32 males, 6 females; mean age 41.9 ± 12.8 years) with invasive macroprolactinomas (baseline median prolactin: 2530 (1726-5451) ng/mL, mean longest tumor diameter: 36.4 ± 12.8 mm) who were followed for at least one year under cabergoline therapy. Prolactin levels and tumor volume changes were analyzed at early and late follow-ups. Patients were classified as good responders (GRs) or poor responders (PRs) based on their first-year outcomes.
resultsAt the first year, 17 patients (44.7%) achieved a GR. Baseline parameters were comparable between groups, but GRs had significantly higher normoprolactinemia rates (70.6% vs. 23.8%,p = 0.004) and greater tumor shrinkage (57.3 ± 15.6% vs. 41.9 ± 21.9%,p = 0.02) at 3-6 months. An early tumor shrinkage cut-off rate of 44.9% (88% sensitivity, 62% specificity) or an early prolactin cut-off level of 30 ng/mL (75% sensitivity, 77% specificity) were identified as good predictors of GR in the first-year. All GRs maintained normoprolactinemia and ≥ 50% tumor shrinkage, while 33.3% and 42.9% of PRs failed to meet these goals, respectively, at the last visit (p = 0.009, p = 0.002). Three of PRs required surgery during follow-up.
conclusionsApproximately half of invasive prolactinoma patients achieved the composite goal within one year of cabergoline therapy. Early follow-up studies, rather than baseline characteristics, are strong predictors of treatment success.
Indexed as
Identifiers
40064718What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.